151 related articles for article (PubMed ID: 4352112)
1. Nasopharyngeal carcinoma and Epstein-Barr virus. II. Clinical course and the anti-VCA antibody.
Lynn T; Tu S; Hirayama T; Kawamura A
Jpn J Exp Med; 1973 Apr; 43(2):135-44. PubMed ID: 4352112
[No Abstract] [Full Text] [Related]
2. Nasopharyngeal carcinoma and Epstein-Barr virus. I. Factors related to the anti-VCA antibody.
Lynn T; Tu S; Hirayama T; Kawamura A
Jpn J Exp Med; 1973 Apr; 43(2):121-33. PubMed ID: 4352111
[No Abstract] [Full Text] [Related]
3. Epstein-Barr virus-associated antibodies and serum biochemistry in nasopharyngeal carcinoma.
Lynn TC; Hsieh RP; Chuang CY; Huang SC; Hsieh T; Tu SM
Laryngoscope; 1984 Nov; 94(11 Pt 1):1485-8. PubMed ID: 6092804
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
5. [The diagnosis of nasopharyngeal carcinoma (author's transl)].
Arnold W; Nakazima A; Wang YB; Vosteen KH; Brunner H; Göbel U
HNO; 1980 Aug; 28(8):247-60. PubMed ID: 6254933
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to Epstein-Barr virus-related antigens in nasopharyngeal carcinoma. Comparison of active cases with long-term survivors.
Henle W; Ho HC; Henle G; Kwan HC
J Natl Cancer Inst; 1973 Aug; 51(2):361-9. PubMed ID: 4358130
[No Abstract] [Full Text] [Related]
7. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of nasopharyngeal carcinoma by Epstein-Barr virus antibody titer.
Lynn T; Hsu M; Hsieh T; Tu S
Arch Otolaryngol; 1977 Mar; 103(3):128-32. PubMed ID: 189741
[TBL] [Abstract][Full Text] [Related]
9. Nasopharyngeal carcinoma and Epstein-Barr virus. III. The detection of anti-nuclear antibodies.
Lynn TC; Hsu MM; Hsieh T; Tu SM; Hamajima K
Jpn J Exp Med; 1976 Oct; 46(5):289-95. PubMed ID: 189106
[TBL] [Abstract][Full Text] [Related]
10. Studies of the Epstein-Barr herpesvirus relationship with Hodgkin's disease and the use of virus immunological markers in differential diagnostics of nasopharyngeal carcinoma.
Mazurenko NP; Gurtsevich VE; Stepina VN; Plakhov IV
Arch Geschwulstforsch; 1983; 53(3):253-9. PubMed ID: 6311138
[No Abstract] [Full Text] [Related]
11. Anti-Epstein Barr virus antibody in nasopharyngeal carcinoma.
Hsu MM; Chiou JF; McCabe BF
Ann Otol Rhinol Laryngol; 1974; 83(1):19-25. PubMed ID: 4359674
[No Abstract] [Full Text] [Related]
12. Epstein-Barr virus is not associated with head and neck neoplasms other than nasopharyngeal carcinoma.
Kottaridis SD; Goula I; Kiparissiadis P
Neoplasma; 1982; 29(3):327-31. PubMed ID: 6290911
[No Abstract] [Full Text] [Related]
13. Nasopharyngeal carcinoma and Epstein-Barr virus--associated serologic markers.
Tam JS; Murray HG
Ear Nose Throat J; 1990 Apr; 69(4):261-7. PubMed ID: 2161732
[TBL] [Abstract][Full Text] [Related]
14. Further studies on antibodies to early antigens induced by Epstein-Barr virus in nasopharyngeal carcinoma patients.
Ida S; Hinuma Y; Chu CT; Chiou JF; Lai JG
Gan; 1973 Dec; 64(6):545-53. PubMed ID: 4360581
[No Abstract] [Full Text] [Related]
15. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls.
Henle W; Henle G; Ho JH
IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525
[No Abstract] [Full Text] [Related]
16. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
Mazeron MC
Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
[TBL] [Abstract][Full Text] [Related]
17. Malaria antibody levels in patients with nasopharyngeal carcinoma.
Yadav M; Prasad U
Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462
[TBL] [Abstract][Full Text] [Related]
18. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in nasopharyngeal carcinoma.
Chatani M; Teshima T; Inoue T; Yoshino K; Ikegami N; Hirai K; Shimakage M
Laryngoscope; 1991 Jun; 101(6 Pt 1):626-9. PubMed ID: 1645832
[TBL] [Abstract][Full Text] [Related]
19. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
Wilmes E; Wolf H; Deinhardt F; Naumann HH
Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
[TBL] [Abstract][Full Text] [Related]
20. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
